Search
Back

Diroximel Fumarate

CAS 1577222-14-0
Diroximel Fumarate

General Information

Diroximel fumarate, also known as ALKS-8700, is in Phase III clinical trials for the treatment of relapsing remitting multiple sclerosis, which is the most common form of multiple sclerosis (MS). Relapsing remitting MS is characterized by episodes of worsening neurologic functioning followed by partial or complete recovery periods free of disease progression.


About the API

Technology Synthetic
Therapeutic category Immunology
Systematic Name 4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.